CN104884447B - 卤素取代杂环化合物 - Google Patents
卤素取代杂环化合物 Download PDFInfo
- Publication number
- CN104884447B CN104884447B CN201380068911.1A CN201380068911A CN104884447B CN 104884447 B CN104884447 B CN 104884447B CN 201380068911 A CN201380068911 A CN 201380068911A CN 104884447 B CN104884447 B CN 104884447B
- Authority
- CN
- China
- Prior art keywords
- bases
- amino
- carbonyl
- thiophene
- cyclopropane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710949188.8A CN107698555B (zh) | 2012-12-28 | 2013-12-27 | 卤素取代杂环化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012-286425 | 2012-12-28 | ||
| JP2012286425 | 2012-12-28 | ||
| JP2013097171 | 2013-05-02 | ||
| JP2013-097171 | 2013-05-02 | ||
| PCT/JP2013/085277 WO2014104372A1 (ja) | 2012-12-28 | 2013-12-27 | ハロゲン置換へテロ環化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710949188.8A Division CN107698555B (zh) | 2012-12-28 | 2013-12-27 | 卤素取代杂环化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104884447A CN104884447A (zh) | 2015-09-02 |
| CN104884447B true CN104884447B (zh) | 2017-10-10 |
Family
ID=51021433
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380068911.1A Active CN104884447B (zh) | 2012-12-28 | 2013-12-27 | 卤素取代杂环化合物 |
| CN201710949188.8A Active CN107698555B (zh) | 2012-12-28 | 2013-12-27 | 卤素取代杂环化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710949188.8A Active CN107698555B (zh) | 2012-12-28 | 2013-12-27 | 卤素取代杂环化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10000463B2 (enExample) |
| EP (2) | EP2940013B1 (enExample) |
| JP (3) | JP6176258B2 (enExample) |
| KR (1) | KR102189166B1 (enExample) |
| CN (2) | CN104884447B (enExample) |
| AU (1) | AU2013366898B2 (enExample) |
| BR (1) | BR112015015275B1 (enExample) |
| CA (1) | CA2896701C (enExample) |
| DK (2) | DK2940013T3 (enExample) |
| ES (2) | ES2667798T3 (enExample) |
| MX (1) | MX369801B (enExample) |
| RU (2) | RU2649398C2 (enExample) |
| WO (1) | WO2014104372A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015015275B1 (pt) * | 2012-12-28 | 2021-12-14 | Ube Industries, Ltd | Composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso |
| SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| JP2014231508A (ja) * | 2013-05-02 | 2014-12-11 | 宇部興産株式会社 | ハロゲン置換へテロ環化合物 |
| CN106458964B (zh) * | 2014-06-27 | 2019-11-22 | 宇部兴产株式会社 | 卤素取代杂环化合物的盐 |
| WO2017086430A1 (ja) * | 2015-11-20 | 2017-05-26 | 宇部興産株式会社 | Ｎａｓｈの治療又は予防のための医薬組成物 |
| CN114206832B (zh) * | 2019-07-30 | 2025-04-04 | 大正制药株式会社 | 拮抗lpa1受体的脲化合物 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| JP7591066B2 (ja) | 2020-06-03 | 2024-11-27 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CN111909170B (zh) * | 2020-09-11 | 2022-08-12 | 吉林奥来德光电材料股份有限公司 | 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件 |
| WO2022240879A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| JP7709612B2 (ja) | 2021-12-08 | 2025-07-16 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| CA3222642A1 (en) | 2022-12-12 | 2024-06-12 | Bmic Llc | Downstream uses for briquettes and other forms of powder from asphalt shingle waste |
| WO2026094986A1 (en) * | 2024-11-01 | 2026-05-07 | Hilung Inc. | Dry powder pharmaceutical composition for inhalation comprising small molecule lpa1 antagonist and process for preparation thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194850A1 (en) * | 2003-08-05 | 2006-08-31 | Ajinomoto Co. Inc | Novel azole compound |
| CN102245584A (zh) * | 2008-12-15 | 2011-11-16 | 艾米拉制药公司 | 溶血磷脂酶受体的拮抗剂 |
| WO2012078593A2 (en) * | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| WO2012138797A1 (en) * | 2011-04-05 | 2012-10-11 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1258484E (pt) | 2000-02-18 | 2009-04-03 | Kyowa Hakko Kirin Co Ltd | Novos compostos de isoxazol e de tiazol e sua utilização enquanto fármacos |
| EP1364659B1 (en) | 2001-02-08 | 2009-11-11 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| EP2342189A2 (en) | 2008-09-29 | 2011-07-13 | Eli Lilly And Company | Selective estrogen receptor modulator for the treatment of osteoarthritis |
| GB2470833B (en) | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| WO2011091167A2 (en) | 2010-01-22 | 2011-07-28 | The General Hospital Corporation | Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| WO2011159635A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| WO2011159632A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye |
| CN103596566B (zh) | 2010-12-07 | 2017-08-25 | 阿米拉制药公司 | 多环lpa1拮抗剂及其使用 |
| CA2844982A1 (en) | 2011-08-15 | 2013-02-21 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| BR112015015275B1 (pt) * | 2012-12-28 | 2021-12-14 | Ube Industries, Ltd | Composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso |
-
2013
- 2013-12-27 BR BR112015015275-9A patent/BR112015015275B1/pt active IP Right Grant
- 2013-12-27 EP EP13868493.1A patent/EP2940013B1/en active Active
- 2013-12-27 KR KR1020157019230A patent/KR102189166B1/ko active Active
- 2013-12-27 ES ES13868493.1T patent/ES2667798T3/es active Active
- 2013-12-27 WO PCT/JP2013/085277 patent/WO2014104372A1/ja not_active Ceased
- 2013-12-27 JP JP2014554626A patent/JP6176258B2/ja active Active
- 2013-12-27 RU RU2015131139A patent/RU2649398C2/ru active
- 2013-12-27 MX MX2015008479A patent/MX369801B/es active IP Right Grant
- 2013-12-27 DK DK13868493.1T patent/DK2940013T3/en active
- 2013-12-27 ES ES18157384T patent/ES2825031T3/es active Active
- 2013-12-27 DK DK18157384.1T patent/DK3360869T3/da active
- 2013-12-27 EP EP18157384.1A patent/EP3360869B1/en active Active
- 2013-12-27 RU RU2018109925A patent/RU2756506C2/ru active
- 2013-12-27 CA CA2896701A patent/CA2896701C/en active Active
- 2013-12-27 CN CN201380068911.1A patent/CN104884447B/zh active Active
- 2013-12-27 AU AU2013366898A patent/AU2013366898B2/en active Active
- 2013-12-27 CN CN201710949188.8A patent/CN107698555B/zh active Active
-
2015
- 2015-06-26 US US14/752,623 patent/US10000463B2/en active Active
-
2017
- 2017-07-11 JP JP2017135811A patent/JP6414286B2/ja active Active
-
2018
- 2018-05-08 US US15/974,494 patent/US10597375B2/en active Active
- 2018-10-03 JP JP2018188246A patent/JP6569792B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194850A1 (en) * | 2003-08-05 | 2006-08-31 | Ajinomoto Co. Inc | Novel azole compound |
| CN102245584A (zh) * | 2008-12-15 | 2011-11-16 | 艾米拉制药公司 | 溶血磷脂酶受体的拮抗剂 |
| WO2012078593A2 (en) * | 2010-12-07 | 2012-06-14 | Amira Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonists and uses thereof |
| WO2012138797A1 (en) * | 2011-04-05 | 2012-10-11 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107698555B (zh) | 卤素取代杂环化合物 | |
| CN106458964B (zh) | 卤素取代杂环化合物的盐 | |
| CN106008340A (zh) | 稠环衍生物、其制备方法、中间体、药物组合物及应用 | |
| TWI748996B (zh) | 嘧啶類七元環化合物、其製備方法、藥用組合物及其應用 | |
| CN106478500A (zh) | 羧酸取代的（杂）芳环类衍生物及其制备方法和用途 | |
| WO2017041732A1 (zh) | 一类用于治疗或预防高尿酸血症或痛风的化合物 | |
| CN110337433B (zh) | 用于调节sgk活性的化合物和药物组合物及其方法 | |
| CN105130888A (zh) | 炔基吡啶类脯氨酰羟化酶抑制剂、其制备方法和医药用途 | |
| CN104039766A (zh) | 药物化合物 | |
| CN109748914B (zh) | 吡啶并嘧啶类化合物及其应用 | |
| CN111356695B (zh) | 新的三环化合物 | |
| CN106279119B (zh) | 一种新型激酶抑制剂的制备及其应用 | |
| CN108727267B (zh) | 一类urat1抑制剂及其应用 | |
| WO2021104486A1 (zh) | 一种含苯环的化合物及其应用 | |
| CN106458920A (zh) | 炔基吲唑衍生物及其用途 | |
| CN111801314A (zh) | Ask1抑制剂化合物及其用途 | |
| CN102532123B (zh) | 噻唑-5-甲酰胺化合物、及其制法和药物组合物与用途 | |
| WO2025252099A1 (zh) | 一种吡咯并六元芳环化合物及其制备方法和应用 | |
| WO2024104317A1 (zh) | 抑制15-pgdh的化合物及其用途 | |
| HK40082822B (zh) | 新型酸分泌抑制剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: Yamaguchi Prefecture, Japan Patentee after: Ube Co.,Ltd. Address before: Yamaguchi Japan Patentee before: UBE INDUSTRIES, Ltd. |
|
| CP03 | Change of name, title or address |